Astrocytoma, IDH-Mutant, Grade 3 Clinical Trials in Pittsburgh, Pennsylvania
3 recruitingPittsburgh, Pennsylvania
Showing 1–3 of 3 trials
Recruiting
Phase 3
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Astrocytoma, IDH-Mutant, Grade 3
Alliance for Clinical Trials in Oncology408 enrolled75 locationsNCT07215910
Recruiting
Phase 1
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-MutantRecurrent Adult Diffuse Midline Glioma, H3 K27-Mutant+4 more
National Cancer Institute (NCI)30 enrolled42 locationsNCT06860594
Recruiting
Phase 3
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
GliomaAstrocytoma, IDH-Mutant, Grade 2Astrocytoma, Grade IV+5 more
Nuvation Bio Inc.365 enrolled55 locationsNCT05303519